{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:56:05Z","timestamp":1790823365804,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01469-1","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:14:40Z","timestamp":1790759680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Roles of Lipoprotein(a) in Atherosclerosis \u2013 Minding the Knowledge Gaps"],"prefix":"10.1007","volume":"28","author":[{"given":"Michael B.","family":"Boffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Assini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"39","key":"1469_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346.","journal-title":"Eur Heart J"},{"issue":"1","key":"1469_CR2","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1469_CR3","doi-asserted-by":"crossref","unstructured":"Blumenthal RS, Morris PB, Gaudino M et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026.","DOI":"10.1161\/CIR.0000000000001475"},{"issue":"6","key":"1469_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MOL.0000000000001016","volume":"36","author":"MB Boffa","year":"2025","unstructured":"Boffa MB, Koschinsky ML, Hegele RA. Evolving guidelines on lipoprotein(a). Curr Opin Lipidol. 2025;36(6):300\u20139.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"1469_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41569-026-01278-8","volume":"23","author":"ML Koschinsky","year":"2026","unstructured":"Koschinsky ML, Boffa MB. Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events? Nat Rev Cardiol. 2026;23(5):293\u20135.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1469_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","volume":"83","author":"E Bjornson","year":"2024","unstructured":"Bjornson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis. J Am Coll Cardiol. 2024;83(3):385\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1469_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MOL.0000000000001000","volume":"36","author":"JM Assini","year":"2025","unstructured":"Assini JM, Boffa MB, Koschinsky ML. The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets. Curr Opin Lipidol. 2025;36(5):268\u201375.","journal-title":"Curr Opin Lipidol"},{"issue":"6144","key":"1469_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","volume":"330","author":"JW McLean","year":"1987","unstructured":"McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330(6144):132\u20137.","journal-title":"Nature"},{"issue":"19","key":"1469_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1042\/BCJ20240037","volume":"481","author":"MB Boffa","year":"2024","unstructured":"Boffa MB, Koschinsky ML. Lipoprotein(a) and cardiovascular disease. Biochem J. 2024;481(19):1277\u201396.","journal-title":"Biochem J"},{"issue":"1","key":"1469_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11883-025-01365-0","volume":"27","author":"P Shah","year":"2025","unstructured":"Shah P, King S, Trabanino S, Parsa S, Chen T, Rodriguez F. Ancestral variation in Lp(a): epidemiology, isoform diversity, and testing. Curr Atheroscler Rep. 2025;27(1):117.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"1469_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/ATVBAHA.121.317335","volume":"42","author":"A Youssef","year":"2022","unstructured":"Youssef A, Clark JR, Marcovina SM, Boffa MB, Koschinsky ML. Apo(a) and apoB interact noncovalently within hepatocytes: implications for regulation of Lp(a) levels by modulation of apoB secretion. Arterioscler Thromb Vasc Biol. 2022;42(3):289\u2013304.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"32","key":"1469_CR12","doi-asserted-by":"publisher","first-page":"9919","DOI":"10.1021\/bi060283t","volume":"45","author":"L Becker","year":"2006","unstructured":"Becker L, Nesheim ME, Koschinsky ML. Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation. Biochemistry. 2006;45(32):9919\u201328.","journal-title":"Biochemistry"},{"issue":"41","key":"1469_CR13","doi-asserted-by":"publisher","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","volume":"270","author":"MJ Callow","year":"1995","unstructured":"Callow MJ, Rubin EM. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo. J Biol Chem. 1995;270(41):23914\u20137.","journal-title":"J Biol Chem"},{"issue":"10","key":"1469_CR14","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1194\/jlr.M040733","volume":"54","author":"G Leibundgut","year":"2013","unstructured":"Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54(10):2815\u201330.","journal-title":"J Lipid Res"},{"issue":"11","key":"1469_CR15","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.1074\/jbc.270.11.6227","volume":"270","author":"A Ernst","year":"1995","unstructured":"Ernst A, Helmhold M, Brunner C, Petho-Schramm A, Armstrong VW, Muller HJ. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32\u201336 of human apolipoprotein(a). J Biol Chem. 1995;270(11):6227\u201334.","journal-title":"J Biol Chem"},{"issue":"6","key":"1469_CR16","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1172\/JCI119671","volume":"100","author":"SD Hughes","year":"1997","unstructured":"Hughes SD, Lou XJ, Ighani S, et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest. 1997;100(6):1493\u2013500.","journal-title":"J Clin Invest"},{"issue":"48","key":"1469_CR17","doi-asserted-by":"publisher","first-page":"15777","DOI":"10.1021\/bi00048a023","volume":"34","author":"BR Gabel","year":"1995","unstructured":"Gabel BR, Koschinsky MI. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry. 1995;34(48):15777\u201384.","journal-title":"Biochemistry"},{"issue":"19","key":"1469_CR18","doi-asserted-by":"publisher","first-page":"8712","DOI":"10.1016\/S0021-9258(19)84439-3","volume":"261","author":"GM Fless","year":"1986","unstructured":"Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem. 1986;261(19):8712\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"1469_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/PL00013141","volume":"44","author":"R Lawn","year":"1997","unstructured":"Lawn R, Patthy L, Pesole G, Saccone C. Apolipoproteins(a): a puzzling evolutionary story. J Mol Evol. 1997;44(2):234\u20136.","journal-title":"J Mol Evol"},{"key":"1469_CR20","doi-asserted-by":"crossref","unstructured":"Yeang C, Cotter B, Tsimikas S. Experimental animal models evaluating the causal role of lipoprotein(a) in atherosclerosis and aortic stenosis. Cardiovasc Drugs Ther 2016.","DOI":"10.1007\/s10557-015-6634-1"},{"key":"1469_CR21","doi-asserted-by":"publisher","first-page":"117150","DOI":"10.1016\/j.atherosclerosis.2023.05.019","volume":"384","author":"JM Assini","year":"2023","unstructured":"Assini JM, Clark JR, Youssef A, et al. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner. Atherosclerosis. 2023;384:117150.","journal-title":"Atherosclerosis"},{"key":"1469_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","volume":"349","author":"ML Koschinsky","year":"2022","unstructured":"Koschinsky ML, Boffa MB. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. Atherosclerosis. 2022;349:92\u2013100.","journal-title":"Atherosclerosis"},{"issue":"3","key":"1469_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","volume":"21","author":"S Tsimikas","year":"2024","unstructured":"Tsimikas S, Witztum JL. Oxidized phospholipids in cardiovascular disease. Nat Rev Cardiol. 2024;21(3):170\u201391.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"1469_CR24","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","volume":"49","author":"C Bergmark","year":"2008","unstructured":"Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230\u20139.","journal-title":"J Lipid Res"},{"issue":"25","key":"1469_CR25","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","volume":"109","author":"S Tsimikas","year":"2004","unstructured":"Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109(25):3164\u201370.","journal-title":"Circulation"},{"issue":"12","key":"1469_CR26","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1194\/jlr.M060210","volume":"56","author":"CA Scipione","year":"2015","unstructured":"Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015;56(12):2273\u201385.","journal-title":"J Lipid Res"},{"issue":"10","key":"1469_CR27","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","volume":"126","author":"JG Schnitzler","year":"2020","unstructured":"Schnitzler JG, Hoogeveen RM, Ali L, et al. Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res. 2020;126(10):1346\u201359.","journal-title":"Circ Res"},{"issue":"8","key":"1469_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","volume":"134","author":"FM van der Valk","year":"2016","unstructured":"van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611\u201324.","journal-title":"Circulation"},{"issue":"12","key":"1469_CR29","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1194\/jlr.P030890","volume":"53","author":"RA van Dijk","year":"2012","unstructured":"van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res. 2012;53(12):2773\u201390.","journal-title":"J Lipid Res"},{"issue":"11","key":"1469_CR30","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","volume":"47","author":"S Tsimikas","year":"2006","unstructured":"Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol. 2006;47(11):2219\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1469_CR31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","volume":"27","author":"S Kiechl","year":"2007","unstructured":"Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27(8):1788\u201395.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"1469_CR32","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","volume":"41","author":"LCA Stiekema","year":"2020","unstructured":"Stiekema LCA, Prange KHM, Hoogeveen RM, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020;41(24):2262\u201371.","journal-title":"Eur Heart J"},{"issue":"3","key":"1469_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. AKCEA-APO-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"issue":"8","key":"1469_CR34","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1194\/jlr.P027235","volume":"53","author":"K Arai","year":"2012","unstructured":"Arai K, Orsoni A, Mallat Z, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res. 2012;53(8):1670\u20138.","journal-title":"J Lipid Res"},{"issue":"18","key":"1469_CR35","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","volume":"81","author":"TC Gilliland","year":"2023","unstructured":"Gilliland TC, Liu Y, Mohebi R, et al. Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes. J Am Coll Cardiol. 2023;81(18):1780\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"1469_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2022.06.1020","volume":"354","author":"R Clarke","year":"2022","unstructured":"Clarke R, Hammami I, Sherliker P, et al. Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. Atherosclerosis. 2022;354:15\u201322.","journal-title":"Atherosclerosis"},{"key":"1469_CR37","doi-asserted-by":"publisher","first-page":"1130162","DOI":"10.3389\/fcvm.2023.1130162","volume":"10","author":"MB Lorey","year":"2023","unstructured":"Lorey MB, Youssef A, Aikas L, et al. Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages. Front Cardiovasc Med. 2023;10:1130162.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1469_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/ATVBAHA.123.319937","volume":"44","author":"KE Dzobo","year":"2024","unstructured":"Dzobo KE, Cupido AJ, Mol BM, et al. Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation. Arterioscler Thromb Vasc Biol. 2024;44(3):720\u201340.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1469_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","volume":"349","author":"MB Boffa","year":"2022","unstructured":"Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis. 2022;349:72\u201381.","journal-title":"Atherosclerosis"},{"issue":"12","key":"1469_CR40","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1194\/jlr.P094763","volume":"60","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Marar TT, Yeang C, et al. Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. J Lipid Res. 2019;60(12):2082\u20139.","journal-title":"J Lipid Res"},{"issue":"2","key":"1469_CR41","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jtha.2025.10.009","volume":"24","author":"JR Clark","year":"2026","unstructured":"Clark JR, Sutherland FS, Assini JM, et al. Lipoprotein(a) prolongs ex vivo plasma clot lysis times through effects on clot formation rate and fibrin structure. J Thromb Haemost. 2026;24(2):701\u201315.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"1469_CR42","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1016\/j.thromres.2012.06.005","volume":"130","author":"A Undas","year":"2012","unstructured":"Undas A, Ciesla-Dul M, Drazkiewicz T, Sadowski J. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res. 2012;130(3):e184\u2013187.","journal-title":"Thromb Res"},{"issue":"1","key":"1469_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11239-018-1769-0","volume":"47","author":"AA Skuza","year":"2019","unstructured":"Skuza AA, Polak M, Undas A. Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties. J Thromb Thrombolysis. 2019;47(1):8\u201315.","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"1469_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","volume":"4","author":"A Undas","year":"2006","unstructured":"Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost. 2006;4(5):973\u20135.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"1469_CR45","doi-asserted-by":"publisher","first-page":"e1002","DOI":"10.1016\/j.jacl.2024.08.004","volume":"18","author":"D Bruwer","year":"2024","unstructured":"Bruwer D, de Lange-Loots Z, Koschinsky ML, Boffa MB, Pieters M. Fibrinogen and plasma clot properties are associated with apolipoprotein B and apolipoprotein B-containing lipoproteins in Africans. J Clin Lipidol. 2024;18(6):e1002\u201314.","journal-title":"J Clin Lipidol"},{"issue":"9","key":"1469_CR46","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","volume":"18","author":"ML Rand","year":"1998","unstructured":"Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998;18(9):1393\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1469_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0037-1615654","volume":"85","author":"C Martinez","year":"2001","unstructured":"Martinez C, Rivera J, Loyau S, et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost. 2001;85(4):686\u201393.","journal-title":"Thromb Haemost"},{"issue":"5","key":"1469_CR48","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/09537104.2020.1802412","volume":"32","author":"P Zhu","year":"2021","unstructured":"Zhu P, Tang XF, Song Y, et al. Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention. Platelets. 2021;32(5):684\u20139.","journal-title":"Platelets"},{"issue":"3","key":"1469_CR49","doi-asserted-by":"publisher","first-page":"e033562","DOI":"10.1161\/JAHA.123.033562","volume":"13","author":"HS Bhatia","year":"2024","unstructured":"Bhatia HS, Trainor P, Carlisle S, et al. Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2024;13(3):e033562.","journal-title":"J Am Heart Assoc"},{"key":"1469_CR50","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.ajpc.2024.100674","volume":"18","author":"AC Razavi","year":"2024","unstructured":"Razavi AC, Richardson LC, Coronado F, et al. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a). Am J Prev Cardiol. 2024;18:100674.","journal-title":"Am J Prev Cardiol"},{"issue":"14","key":"1469_CR51","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","volume":"80","author":"P Lacaze","year":"2022","unstructured":"Lacaze P, Bakshi A, Riaz M, et al. Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes. J Am Coll Cardiol. 2022;80(14):1287\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1469_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11883-025-01296-w","volume":"27","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Bhatia HS. Role of Aspirin in Reducing Risk for Atherosclerotic Cardiovascular Disease in Individuals with Elevated Lipoprotein(a). Curr Atheroscler Rep. 2025;27(1):49.","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"1469_CR53","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1074\/jbc.M309705200","volume":"279","author":"M Pellegrino","year":"2004","unstructured":"Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC, et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem. 2004;279(8):6526\u201333.","journal-title":"J Biol Chem"},{"issue":"45","key":"1469_CR54","doi-asserted-by":"publisher","first-page":"30503","DOI":"10.1074\/jbc.M802648200","volume":"283","author":"T Cho","year":"2008","unstructured":"Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV(10\u2019), mediates increased endothelial cell contraction and permeability via a Rho\/Rho kinase\/MYPT1-dependent pathway. J Biol Chem. 2008;283(45):30503\u201312.","journal-title":"J Biol Chem"},{"issue":"3","key":"1469_CR55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1091\/mbc.e12-08-0637","volume":"24","author":"T Cho","year":"2013","unstructured":"Cho T, Romagnuolo R, Scipione C, Boffa MB, Koschinsky ML. Apolipoprotein(a) stimulates nuclear translocation of beta-catenin: a novel pathogenic mechanism for lipoprotein(a). Mol Biol Cell. 2013;24(3):210\u201321.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"1469_CR56","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.123.066822","volume":"149","author":"MA Rogers","year":"2024","unstructured":"Rogers MA, Bartoli-Leonard F, Zheng KH, et al. Major Facilitator Superfamily Domain Containing 5 inhibition reduces lipoprotein(a) uptake and calcification in valvular heart disease. Circulation. 2024;149(5):391\u2013401.","journal-title":"Circulation"},{"key":"1469_CR57","doi-asserted-by":"publisher","first-page":"119174","DOI":"10.1016\/j.atherosclerosis.2025.119174","volume":"403","author":"TG Khan","year":"2025","unstructured":"Khan TG, Bragazzi Cunha J, Raut C, et al. Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening. Atherosclerosis. 2025;403:119174.","journal-title":"Atherosclerosis"},{"issue":"19","key":"1469_CR58","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1161\/CIRCULATIONAHA.120.052023","volume":"144","author":"F Fasolo","year":"2021","unstructured":"Fasolo F, Jin H, Winski G, et al. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. Circulation. 2021;144(19):1567\u201383.","journal-title":"Circulation"},{"key":"1469_CR59","doi-asserted-by":"publisher","first-page":"778919","DOI":"10.3389\/fcvm.2022.778919","volume":"9","author":"MA Rogers","year":"2022","unstructured":"Rogers MA, Atkins SK, Zheng KH, et al. Lipoprotein(a) induces vesicular cardiovascular calcification revealed with single-extracellular vesicle analysis. Front Cardiovasc Med. 2022;9:778919.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"1469_CR60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","volume":"79","author":"A Mehta","year":"2022","unstructured":"Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol. 2022;79(8):757\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1469_CR61","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","volume":"9","author":"NS Nurmohamed","year":"2024","unstructured":"Nurmohamed NS, Gaillard EL, Malkasian S, et al. Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation. JAMA Cardiol. 2024;9(9):826\u201334.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1469_CR62","doi-asserted-by":"publisher","first-page":"100820","DOI":"10.1016\/j.jlr.2025.100820","volume":"66","author":"RS Rosenson","year":"2025","unstructured":"Rosenson RS, Tate AM, Grushko OG, et al. Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease. J Lipid Res. 2025;66(6):100820.","journal-title":"J Lipid Res"},{"issue":"3","key":"1469_CR63","doi-asserted-by":"publisher","first-page":"e430","DOI":"10.1016\/j.jacl.2024.02.003","volume":"18","author":"E Zisman","year":"2024","unstructured":"Zisman E, Hossain M, Funderburg NT, et al. Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection. J Clin Lipidol. 2024;18(3):e430\u201343.","journal-title":"J Clin Lipidol"},{"issue":"17","key":"1469_CR64","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","volume":"73","author":"KH Zheng","year":"2019","unstructured":"Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"1469_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.athplu.2024.07.001","volume":"57","author":"MW Yeung","year":"2024","unstructured":"Yeung MW, Said MA, van de Vegte YJ, Verweij N, Dullaart RPF, van der Harst P. Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease. Atheroscler Plus. 2024;57:19\u201325.","journal-title":"Atheroscler Plus"},{"issue":"1","key":"1469_CR66","doi-asserted-by":"publisher","first-page":"8538","DOI":"10.1038\/s41598-025-93518-z","volume":"15","author":"C Li","year":"2025","unstructured":"Li C, Li M, Wang Z. There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease. Sci Rep. 2025;15(1):8538.","journal-title":"Sci Rep"},{"issue":"24","key":"1469_CR67","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","volume":"74","author":"DF Gudbjartsson","year":"2019","unstructured":"Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982\u201394.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1469_CR68","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2337\/dc20-2842","volume":"44","author":"GG Schwartz","year":"2021","unstructured":"Schwartz GG, Szarek M, Bittner VA, et al. Relation of lipoprotein(a) levels to incident Type 2 Diabetes and modification by alirocumab treatment. Diabetes Care. 2021;44(5):1219\u201327.","journal-title":"Diabetes Care"},{"key":"1469_CR69","doi-asserted-by":"publisher","first-page":"120706","DOI":"10.1016\/j.atherosclerosis.2026.120706","volume":"415","author":"SA Sebastian","year":"2026","unstructured":"Sebastian SA, Bimal T, Ayyalu T, Vartak N, Bhatia HS, Tsimikas S. Association of Lp(a) with coronary plaque burden and high-risk plaque features: A meta-analysis of imaging studies. Atherosclerosis. 2026;415:120706.","journal-title":"Atherosclerosis"},{"key":"1469_CR70","doi-asserted-by":"crossref","unstructured":"Fisher R, Gurevitz C, Fisher EA et al. Lipoprotein(a) selectively associates with vulnerable coronary plaque phenotypes in comparison with other established risk markers. Eur Heart J Cardiovasc Imaging 2026.","DOI":"10.1093\/ehjci\/jeag024"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01469-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:03:28Z","timestamp":1790820208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01469-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01469-1","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B.B. has received research contracts from Amgen and Eli Lilly & Company, and has received consulting\/speaking fees from Eli Lilly & Company. M.L.K. has received research contracts from Amgen and Eli Lilly & Company, and has received consulting fees from Novartis and Eli Lilly & Company. J.M.A. reports no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animals or human subjects were used in this study.","order":2,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"98"}}